Panorama 1: A randomized, double-blind, phase 3 study of panobinostat or placebo plus bortezomib and dexamethasone in relapsed or relapsed and refractory multiple myeloma.
Paul G. Richardson
Consultant or Advisory Role - Celgene; Johnson & Johnson; Millennium; Novartis
Vania T.M. Hungria
Consultant or Advisory Role - Novartis
Sung-Soo Yoon
No relevant relationships to disclose
Meral Beksac
Consultant or Advisory Role - Amgen; Celgene; Janssen-Cilag; Novartis
Honoraria - Amgen; Celgene; Janssen-Cilag
Meletios A. Dimopoulos
Consultant or Advisory Role - Novartis
Ashraf Elghandour
No relevant relationships to disclose
Wieslaw W. Jedrzejczak
Honoraria - Novartis
Research Funding - Novartis
Other Remuneration - Novartis
Andreas Guenther
Research Funding - Novartis
Expert Testimony - Novartis
Thanyaphong Na Nakorn
No relevant relationships to disclose
Noppadol Siritanaratkul
No relevant relationships to disclose
Robert L. Schlossman
Consultant or Advisory Role - Millennium
Jian Hou
Consultant or Advisory Role - Novartis
Philippe Moreau
Consultant or Advisory Role - Novartis
Sagar Lonial
Consultant or Advisory Role - Bristol-Myers Squibb; Celgene; Millennium; Novartis; Onyx; Sanofi
Jae Hoon Lee
Consultant or Advisory Role - Novartis
Hermann Einsele
Consultant or Advisory Role - Celgene; Janssen; Novartis; Onyx
Honoraria - Celgene; Janssen; Novartis; Onyx
Research Funding - Celgene; Janssen; Novartis; Onyx
Monika Sopala
Employment or Leadership Position - Novartis
Stock Ownership - Novartis
Bourras-Rezki Bengoudifa
Employment or Leadership Position - Novartis
Claudia Corrado
Employment or Leadership Position - Novartis
Stock Ownership - Novartis
Jesùs F. San-Miguel
Consultant or Advisory Role - Bristol-Myers Squibb; Celgene; Janssen; Merck Sharp & Dohme; Millennium; Novartis; Onyx